Subcutaneous and transvenous ICDs in complex anatomy

Defibrillator selection is often framed as a contest between a subcutaneous implantable cardioverter-defibrillator (S-ICD) and a transvenous ICD (TV-ICD). In patients with altered chest or venous anatomy, however, infection risk, pacing needs, shock-vector feasibility and follow-up access may matter more than the device label. The series, Subcutaneous versus Transvenous Defibrillators in Patients with Complex Anatomy: A Comparative Case Series, uses illustrative, representative vignettes to make these trade-offs practical.

These teaching cases are not a prospective trial and cannot establish superiority. They show how multidisciplinary assessment can favour one approach for one patient while excluding it for another. Australian conditions also shape the comparison, including referral through public and private hospitals, Medicare and private-insurance arrangements, remote monitoring across long distances, and oversight by the Therapeutic Goods Administration.

Why anatomy changes the implant choice

Complex anatomy involves more than unusual veins. Prior transvenous implants may leave stenosis, occlusion, fibrosis or infected pockets. Sternotomy, congenital repair, obesity, kyphosis, pectus deformity, chest irradiation and breast surgery can alter tissue planes or leave little space for a generator. Atrial fibrillation, ventricular ectopy, bundle-branch block and ventricular dilatation can also affect sensing and the position of the heart relative to the shock vector.

An S-ICD avoids intracardiac leads and preserves central veins, which is attractive when lead infection, erosion or repeated access has been troublesome. It still requires a subcutaneous pocket and cannot provide bradycardia pacing, antitachycardia pacing or intracardiac diagnostic electrograms. A TV-ICD may therefore be required when pacing is expected, when ECG screening cannot be passed, or when transvenous lead placement offers a more reliable shock vector.

Anatomical suitability is a dynamic judgement. It changes after cardiac surgery, recurrent infection, thrombosis or a revised diagnosis of ventricular arrhythmia. A prior failed transvenous implant should prompt review of why it failed, rather than automatically making an S-ICD the default answer.

Three comparable clinical profiles

Case one was a 58-year-old man with ischaemic cardiomyopathy, sustained ventricular tachycardia, previous pocket infection and bilateral subclavian stenosis. He had no pacing indication. Multidisciplinary review confirmed that his screening ECG and shock vector were acceptable, and an S-ICD was selected to avoid further venous instrumentation. Follow-up focused on wound healing, rhythm burden and prompt review of any inappropriate shock.

Case two was a 72-year-old woman with complete heart block after valve surgery, severe kyphosis and limited venous access. She required reliable pacing, making a TV-ICD the clinically coherent choice despite the difficult approach. The implantation strategy included alternative access planning, infection prophylaxis and an agreed approach to anticoagulation and wound care.

Case three was a 46-year-old man with repaired congenital heart disease, previous transvenous leads and lead-related venous thrombosis. His remaining central veins were unsuitable, and his scar distribution made a conventional pocket less attractive. He had no pacing requirement; after screening and vector assessment, an S-ICD was used. The case illustrates that avoiding veins does not eliminate procedural complexity.

Across the series, the subcutaneous cases avoided lead erosion and central venous instrumentation, while the transvenous case accepted lead-related risk in exchange for pacing. No single pattern settled the debate: vector quality, infection history and the reliability of follow-up were more informative than a device name. These favourable early courses do not replace long-term comparative data.

Operative differences and early recovery

An S-ICD is generally placed in an anterolateral chest pocket and then assessed for sensing and shock vector using ECG markers. A TV-ICD requires venous access, lead placement and a pocket, with an option to tunnel the lead. Both procedures can involve sedation or general anaesthesia. The operative risk is not simply “no lead” versus “lead”: pocket haematoma, infection, pneumothorax and device migration remain relevant for both approaches.

Early review should include wound inspection, programming checks, arrhythmia surveillance and confirmation that the intended rhythm can be sensed and treated appropriately. S-ICD noise or T-wave oversensing can trigger inappropriate shocks, while transvenous lead noise, fracture or insulation failure can cause inappropriate therapy or failure to capture. Anticoagulation and temporary restrictions on heavy upper-body movement should be individualised rather than applied mechanically.

After any shock, patients need clinical review to establish the rhythm and cause. A shock delivered for ventricular fibrillation differs from one triggered by electromagnetic interference, rapid atrial fibrillation or a device artefact. Clear written instructions about wound care, swimming, exercise and driving reduce uncertainty while recovery is under way.

Evidence, surveillance and device follow-up

No large randomised trial has established that S-ICD and TV-ICD systems provide equivalent or unequal survival benefit. Observational studies suggest comparable appropriate shock rates in selected patients. S-ICD avoids certain lead complications, whereas TV-ICD supports pacing and antitachycardia therapy. Selection confounding, ECG screening, programming and follow-up differences limit direct comparisons.

Remote interrogation is central to Australian practice. In Melbourne, Sydney, Brisbane and Perth, home transmitters can reduce clinic visits. In rural New South Wales, Queensland, Western Australia and the Northern Territory, couriered devices, telehealth and occasional travel remain necessary. Remote monitoring is not a substitute for wound checks and should have an agreed pathway for urgent alerts, failed transmissions and suspected infection.

Peer-reviewed updates, special issues and clinical guidance are available through Journal of Arrhythmia. Readers should distinguish arrhythmia publications from advertising and check the publication date, study design, funding and applicable Australian product information before changing management.

Australian practice and patient priorities

Medical devices in Australia are regulated by the Therapeutic Goods Administration under the Therapeutic Goods (Medical Devices) Regulations 2002. S-ICD and TV-ICD models must be included in the Australian Register of Therapeutic Goods before supply, with sponsors responsible for post-market obligations. Clinicians should verify the current approved indication, contraindications and recall status for the exact model rather than assuming that every ICD has the same approved use.

Medicare item numbers contribute to implantation and replacement costs, while private health insurance may cover eligible hospital and device charges. Public and private hospitals can differ in waiting times, procurement and access to particular models, so availability should not dictate medical suitability. Patients should request an itemised estimate, clarify out-of-pocket gaps and ask whether travel, allied health and remote-monitoring costs are covered.

Planning must fit Australian routines: swimming, cycling, contact sports, farm work and long-distance driving affect wound recovery and risk. Clinicians should set activity limits, review fitness to drive after any shock under current state rules and Austroads guidance, and ensure patients know to call 000 rather than drive themselves to hospital. CPR and AED availability in workplaces, clubs and shopping centres remain important community safeguards.

Making the decision together

An effective decision aid should show what each device can and cannot do, not merely list advantages. It should cover pacing, antitachycardia therapy, infection, lead complications, inappropriate shocks, replacement, procedural risk, expected follow-up and out-of-pocket costs. For secondary prevention or unstable disease, the urgency of restoring protection may narrow the choices; for primary prevention, time for screening and shared planning is usually important.

Remote follow-up also requires consent explained in plain terms. In Australia, health-service information is governed by the Privacy Act 1988 and Australian Privacy Principles, while the My Health Records Act 2012 controls aspects of the national digital record. Patients should ask which organisation reviews transmissions, how alerts are handled and whether data are shared with manufacturers. Consumer apps and cloud accounts should not become unapproved clinical monitoring channels.

Clear labelling also matters when online material spans clinical and consumer subjects. The site's cold wallet guide is a practical explainer on a separate topic, not evidence about defibrillators; the same source-checking discipline—identifying the audience, sponsor and evidence level—should be applied to any implant claim found online.

Take the next step

The next step is a referral to an electrophysiology service experienced in structural or congenital heart disease and complex device implantation. In Australia this can start with a GP, specialist or emergency department; bringing prior ECGs, imaging, operative notes, infection records and device information can shorten planning. Larger regional centres can coordinate with local cardiology and remote clinics to reduce repeated travel.

Ask that referral to document anatomy, ECG screening, shock vector, pacing need, infection history, cost and follow-up before a device is selected. Arrange an electrophysiology review and bring the patient’s complete implant and infection history to the appointment.